Show simple item record

Authordc.contributor.authorToro Campos, Rosario 
Authordc.contributor.authorAlgarín Crespo, Cecilia 
Authordc.contributor.authorPeirano Campos, Patricio 
Authordc.contributor.authorPeña, Marcela 
Authordc.contributor.authorMurguia Peniche, Teresa 
Authordc.contributor.authorWu, Steven S. 
Authordc.contributor.authorUauy Dagach-Imbarack, Ricardo 
Admission datedc.date.accessioned2020-06-23T22:03:02Z
Available datedc.date.available2020-06-23T22:03:02Z
Publication datedc.date.issued2020
Cita de ítemdc.identifier.citationBMC Pediatrics (2020) 20:225es_ES
Identifierdc.identifier.other10.1186/s12887-020-02087-9
Identifierdc.identifier.urihttp://repositorio.uchile.cl/handle/2250/175658
Abstractdc.description.abstractBackground: A central aim for pediatric nutrition is to develop infant formula compositionally closer to human milk. Milk fat globule membranes (MFGM) have shown to have functional components that are found in human milk, suggesting that addition of bovine sources of MFGM (bMFGM) to infant formula may promote beneficial outcomes potentially helping to narrow the gap between infants who receive human breast milk or infant formula. The objective of the current study is to determine how the addition of bMFGM in infant formula and consumption in early infancy affects physical growth and brain development when compared to infants fed with a standard formula and a reference group of infants fed with mother's own milk.MethodsSingle center, double-blind, and parallel randomized controlled trial. Planned participant enrollment includes: infants exclusively receiving breast milk (n=200; human milk reference group; HM) and infants whose mothers chose to initiate exclusive infant formula feeding before 4months of age (n=340). The latter were randomized to receive one of two study formulas until 12months of age: 1) cow's milk based infant formula that had docosahexaenoic (DHA) (17mg/100kcal) and arachidonic acid (ARA) (25mg/100kcal); 1.9g protein/100kcal; 1.2mg Fe/100kcal (Standard formula; SF) or 2) a similar infant formula with an added source of bovine MFGM (whey protein-lipid concentrate (Experimental formula; EF). Primary outcomes will be: 1) Physical growth (Body weight, length, and head circumference) at 730days of age; and 2) Cognitive development (Auditory Event-Related Potential) at 730days of age. Data will be analyzed for all participants allocated to each study feeding group.DiscussionThe results of this study will complement the knowledge regarding addition of bMFGM in infant formula including support of healthy growth and improvement of neurodevelopmental outcomes.Trial registrationNCT02626143, registered on December 10th 2015.es_ES
Patrocinadordc.description.sponsorshipMead Johnson Nutrition Company, LLC Mead Johnson Nutritiones_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherBMCes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceBMC Pediatricses_ES
Keywordsdc.subjectInfant formulaes_ES
Keywordsdc.subjectMilk fat globule membranees_ES
Keywordsdc.subjectMFGMes_ES
Keywordsdc.subjectGrowth and developmentes_ES
Keywordsdc.subjectClinical trialses_ES
Keywordsdc.subjectBreast feedinges_ES
Keywordsdc.subjectChilees_ES
Títulodc.titleEffect of feeding mode on infant growth and cognitive function: study protocol of the Chilean infant Nutrition randomized controlled Trial (ChiNuT)es_ES
Document typedc.typeArtículo de revistaes_ES
Catalogueruchile.catalogadorlajes_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile